Patent bill critique
This article was originally published in The Gray Sheet
Executive Summary
The Patent Reform Act (HR 1908) - marked up by the House Judiciary Subcommittee on Courts, the Internet and Intellectual Property May 16 - could "hold serious negative consequences for continued innovation," according to a coalition including the Medical Device Manufacturers Association, venture capital firms and several individual device companies. In a May 15 letter to House and Senate leaders, the group notes potential for provisions in the bill (and its Senate companion S 1145) to create "greater bureaucracy, inability to rely on valid patents, weakened protections against infringement and a decreased access to capital"...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.